This inventor holds 12 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Pfizer Corporation, Amgen Fremont Inc., Abgenix, Inc.. Active years: 1993-2018.
Company Filing History:
11 out of 4,486 
8 out of 78 
1 out of 32 
Years Active: 1993-2018
Title: Innovations of Douglas Charles Hanson
Introduction
Douglas Charles Hanson is a notable inventor based in Niantic, Connecticut, with a remarkable portfolio of 12 patents. His work primarily focuses on advancements in biotechnology, particularly in the development of human monoclonal antibodies.
Latest Patents
One of Hanson's latest patents includes the invention of fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). This patent provides nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules. Specifically, it details contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), particularly from within FR1 and/or CDR1 through CDR3 and/or within FR4. The patent further includes antibodies with similar binding properties and functionality as those disclosed.
Career Highlights
Throughout his career, Douglas has made significant contributions while working with prominent companies such as Pfizer Corporation and Amgen Fremont Inc. His expertise in the field of immunology and biotechnology has led to innovative solutions that enhance therapeutic options.
Collaborations
Some of his notable coworkers include Mark Joseph Neveu and Eileen Elliott Mueller, who have collaborated with him on various projects.
Conclusion
Douglas Charles Hanson is a distinguished inventor whose work in monoclonal antibodies has the potential to impact the field of immunotherapy significantly. His contributions continue to pave the way for advancements in medical science.